Skip to main content
SpringerLink
Log in
Book cover

Oncologic Critical Care pp 1–8Cite as

Alternatives to Blood Products

  • Living reference work entry
  • First Online:

  • 295 Accesses

Abstract

Alternatives to blood products manage anemia and/or thrombocytopenia in patients while avoiding the risks of transfusion. Such strategies help preserve a limited blood supply, reduce exposure to donor blood products and possible transfusion reactions, and control financial costs related to blood. Alternatives can include improving blood production with nutrient supplementation or erythropoietin administration, using surgical techniques such as intraoperative cell salvage or acute normovolemic hemodilution, or administering pharmacologic agents to control bleeding such as antifibrinolytics and purified coagulation factors.

This is a preview of subscription content, log in via an institution.

References

  1. Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24. https://doi.org/10.1001/jama.299.8.914.

    Article  CAS  PubMed  Google Scholar 

  2. Carson JL, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016a;316:2025–35. https://doi.org/10.1001/jama.2016.9185.

    Article  PubMed  Google Scholar 

  3. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016b;10:CD002042. https://doi.org/10.1002/14651858.CD002042.pub4.

    Article  PubMed  Google Scholar 

  4. Crash- trial collaborators, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32. https://doi.org/10.1016/S0140-6736(10)60835-5.

    Article  CAS  Google Scholar 

  5. Dutton RP, et al. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma. 2011;71:12–9. https://doi.org/10.1097/TA.0b013e31821a42cf.

    Article  CAS  PubMed  Google Scholar 

  6. Estcourt LJ, Desborough M, Brunskill SJ, Doree C, Hopewell S, Murphy MF, Stanworth SJ. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database Syst Rev. 2016;3:CD009733. https://doi.org/10.1002/14651858.CD009733.pub3.

    Article  PubMed  Google Scholar 

  7. Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205–13. https://doi.org/10.7326/M14-1589.

    Article  PubMed  Google Scholar 

  8. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):11S–26S. https://doi.org/10.1016/j.amjmed.2003.12.008.

    Article  PubMed  Google Scholar 

  9. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791–800. https://doi.org/10.1056/NEJMoa1006221.

    Article  CAS  PubMed  Google Scholar 

  10. Leyland-Jones B, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016;34:1197–207. https://doi.org/10.1200/JCO.2015.63.5649.

    Article  CAS  PubMed  Google Scholar 

  11. Ludwig H, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45:1603–15. https://doi.org/10.1016/j.ejca.2009.02.003.

    Article  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer and chemotherapy related anemia vol version 2.2018. Bethesda; 2017.

    Google Scholar 

  13. Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22:1217–22. https://doi.org/10.1007/s00520-013-2074-2.

    Article  CAS  PubMed  Google Scholar 

  14. Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32. https://doi.org/10.1056/NEJMoa0907845.

    Article  PubMed  Google Scholar 

  15. Price TH. The RING study: a randomized controlled trial of GCSF-stimulated granulocytes in granulocytopenic patients. Paper presented at the ASH 2014, San Francisco, CA; 2014.

    Google Scholar 

  16. Roback JD, et al. Evidence-based practice guidelines for plasma transfusion. Transfusion. 2010;50:1227–39. https://doi.org/10.1111/j.1537-2995.2010.02632.x.

    Article  PubMed  Google Scholar 

  17. Schiffer CA, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:283–99. https://doi.org/10.1200/JCO.2017.76.1734.

    Article  PubMed  Google Scholar 

  18. Slichter SJ, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362:600–13. https://doi.org/10.1056/NEJMoa0904084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev. 2014;28:95–102. https://doi.org/10.1016/j.blre.2014.03.001.

    Article  CAS  PubMed  Google Scholar 

  20. Tonia T, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407. https://doi.org/10.1002/14651858.CD003407.pub5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    James M. Kelley

Authors
  1. James M. Kelley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M. Kelley .

Editor information

Editors and Affiliations

  1. Department of Critical Care, University of Texas MD Anderson Cancer C Department of Critical Care, Houston, TX, USA

    Joseph L. Nates

  2. Department of Critical Care, University of Texas MD Anderson Cancer C Department of Critical Care, Houston, TX, USA

    Kristen J. Price

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Kelley, J.M. (2019). Alternatives to Blood Products. In: Nates, J., Price, K. (eds) Oncologic Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-74698-2_109-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74698-2_109-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74698-2

  • Online ISBN: 978-3-319-74698-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation